🏀 Introducing "CubanWatch: This Week in Cuban"

Presenting something only I would dream up and feel zero shame about unleashing on the world. “CubanWatch2025. This Week In Cuban.”

The man whom I call “The Patron Saint of Patients” keeps swinging at the parts of American healthcare that most stalwart complacency addicts dare not even try. Does a bro with that kind of power and momentum deserve a fan base that never lets him nap on the job?

I thusly self-proclaim the right to launch my own variant of a weekly (or, depending on how lazy I am, semi-weekly) SportsCenter Recap of this man’s exploits, escapades, and related stentorian gallivanting across media, live appearances, and yelling at Congress.

I will Matthew-ify out every moment that needs a Decubanification for the lay folk who do not have the time or energy to decode pharmaceutical economics after a 12-hour chemo day.

Starting next Friday, I shall troll him with love and continue reminding him that a conversation with me belongs on his calendar, or a spontaneous guest appearance on my podcast.

For now, I’ll leave you with this burning nugget. (That sounded weird but source in comments)

Mark Cuban added another specialty drug to his arsenal this week. I watch that move and see a shot across the bow of a system that hates daylight. My thoughts land next week.

If this hits home, tell me where you have seen it happen. Add a comment or a rage repost and drop your story in the thread. One reply pushes this in front of more people who deal with the same mess.

Are you new here? My condolences and my thanks. Follow along and stay loud with the rest of us. More voices mean more pressure on a system that counts on silence.

SOURCE ➡️

https://www.pharmaceuticalcommerce.com/view/mark-cuban-cost-plus-drug-adds-starjemza-drug-portfolio?utm_source=chatgpt.com